your partner that cares

Value Added Medicines
Oromucosal Delivery
Complex Steriles
OSD Fixed-Dose Combinations

bluepharma
Oromucosal delivery

BlueOS® and BluEase™ are innovative and versatile platforms based on proprietary technologies for the delivery of drug substances through the oral mucosa and gastrointestinal tract.

These patient-centric technologies enable both the incorporation of New Chemical Entities and the repurposing of known drugs, including off-patent molecules.

Crossing boundaries towards patients' needs, prescribers' confidence and payers' outcomes.

CONVENIENCE
Allowing patients and caregivers to succeed:
- Patients with dysphagia and difficulties to swallow, such as pediatrics and geriatrics.
- Emergency situations and non-collaborative patients.
- On-the-go solution.

ADHERENCE AND SAFETY
Giving confidence to prescribers:
- Improved convenience resulting in improved adherence.
- Potential to be less invasive as compared to existing solutions.
- Potential for improved bioavailability and fast onset of action.

SAVINGS
Improved adherence allows for better outcomes and less visits to the hospital, representing savings to payers.

Potential Applications
- Multiple Sclerosis
- Epilepsy
- Parkinson's Disease
- Dementia
- Migraine
- Opioid Overdose
- Alcohol Use Disorder

Oral Thin Films
BlueOS®

Convenient

Prescribers

Payers

Buccal Sprays
BluEase™
**Oral Thin Films**

**Buccal Sprays**

**Oral Dispersible Tablet**

**INDICATION**

**MULTIPLE SCLEROSIS**
- Convenience of administration (pediatrics/dysphagia)
- Improved compliance

**ERECTILE DYSFUNCTION**
- On-the-go and discrete solution
- Alternative to existing solutions

**SUPPORTIVE CARE IN ONCOLOGY**
- Convenience of administration
- Adhesive protective barrier

**MIGRAINE**
- Quickly dissolves on the tongue
- No need to be taken with water

**VALUE PROPOSITION**

**TYPE OF FORMULATION**

**TECHNICAL POC**

**FORMULATION DEVELOPMENT**

**CLINICAL POC**

**SCALE-UP**

**ONGOING**

**OSD Fixed-Dose Combinations**

Development of advanced formulations that aim the modulation of the release profile, overcome barriers such as incompatibilities between molecules and increase of the stability, including **multi-layer tablets**, **micro tablets**, **capsule-in-capsule** and **Hot Mel Extrusion technologies**.

<table>
<thead>
<tr>
<th>Blue073</th>
<th>Candesartan</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Atorvastatin</td>
</tr>
<tr>
<td></td>
<td>Amlodipine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Blue074</th>
<th>Ramipril</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Atorvastatin</td>
</tr>
<tr>
<td></td>
<td>Amlodipine</td>
</tr>
</tbody>
</table>

- Multi-layer technology
- Cardiovascular Therapeutic Field
- Available
Complex Steriles

**Complex Steriles** offer unique advantages and solve major challenges of conventional oral or parenteral drug delivery systems.

### Lipid nanoparticles (LNP)

Bluepharma has more than 25 years of accumulated experience in **lipid-based formulations** (unilamellar liposomes, multivesicular liposomes, targeted and pH sensitive liposomes).

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>VALUE PROPOSITION</th>
<th>TYPE OF FORMULATION</th>
<th>Technical POC</th>
<th>Formulation Development</th>
<th>Non-clinical POC</th>
<th>Clinical POC</th>
<th>Scale-up</th>
</tr>
</thead>
</table>
| Oncology Mesothelioma | • Improved SAFETY and EFFICACY  
• IP granted in major markets WW  
• Orphan Drug Designation granted by FDA and EMA (Mesothelioma) | Liposomal           |               |                         |                 |              | ongoing  |
| Rheumatoid Arthritis | • Improved SAFETY, reducing adverse events  
• Dosing Convenience by decreasing the number of administrations | Liposomal           |               |                         |                 |              | ongoing  |

### Polymer-based microparticles

Bluepharma is developing an **innovative LAI technology** that takes advantage of a hybrid system comprising an in-situ forming hydrogel with embedded microparticles:

- High loading capacity.
- Ability to encapsulate more than one drug.
- Fine-tuning of the drug release profile.
- Minimal or inexisten burst release.

Create value through **Innovation**

How? Contact us!

For business inquiries: business@bluepharma.pt

S. Martinho do Bispo · 3045-016 Coimbra · PORTUGAL

Tel. +351 239 800 300 · Fax +351 239 800 333

www.bluepharmagroup.com

---

Bluepharma’s facilities are EU-GMP certified and approved by MFDS (Republic of Korea), ANVISA (Brazil), MOH Libya, SFDA (Kingdom of Saudi Arabia), Minpromtorg (Russian Federation) and by US FDA (2009, 2012, 2014, 2016, 2019).

We are registered in Iraq, Jordan, Kurdistan, Taiwan, UAE and Vietnam.